Eliem Therapeutics, Inc. (ELYM) News
Filter ELYM News Items
ELYM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ELYM News From Around the Web
Below are the latest news stories about ELIEM THERAPEUTICS INC that investors may wish to consider to help them evaluate ELYM as an investment opportunity.
Eliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's the final day of trading this week and we're starting it with a breakdown of the biggest pre-market stock movers for Friday! |
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday. |
Why Is BioSig Technologies (BSGM) Stock Up 19% Today?BioSig Technologies (BSGM) stock is rising higher on Thursday as subsidiary BioSig AI Sciences joins Nvidia's (NVDA) Inception program. |
Why Is Discover Financial (DFS) Stock Down 13% Today?Discover Financial (DFS) stock is falling on Thursday after the financial services company revealed it's undergoing a regulatory review. |
Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?Eliem Therapeutics (ELYM) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives. |
Why Is Netcapital (NCPL) Stock Down 42% Today?Netcapital (NCPL) stock is dropping on Thursday after the fintech company announced the pricing of a public share offering. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start off the day with a breakdown of the biggest pre-market stock movers worth watching on Thursday morning! |
Eliem Therapeutics Announces Plans to Explore Strategic AlternativesSEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. Eliem has engaged Leerink Partners to act as a strategic advisor in |
Eliem Therapeutics Reports First Quarter Financial Results and Business HighlightsPresented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability Additional preclinical data updates for ETX-123 expected in 2023 SEATTLE and CAMBRIDGE, United Kingdom, May 11, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychi |